Development and Validation of Hplc Method For Analysis of Paclitaxel Drug
Keywords:
Development, Validation, HPLC Method, Analysis and Paclitaxel DrugAbstract
A high-performance liquid chromatography method was established for the quantification of related components in an intravenous emulsion containing a paclitaxel–cholesterol combination. The separation was accomplished via an Agilent Luna® 100 A° C8 (150 X 4.6 mm, 5 µm), maintained at 20C°. The gradient mobile phase comprised acetonitrile and water, with a flow rate of 1.2 ml/min. The ultraviolet detection wavelength was established at 230 nm. The sample solution preparation commenced with the incorporation of anhydrous sodium sulphate to disrupt the emulsion. Methanol and ethyl ether were subsequently introduced to extract the medication and eliminate the emulsion's components using extraction and centrifugation. The method demonstrated selectivity, sensitivity, robustness, linearity, repeatability, accuracy, and appropriateness for quantifying paclitaxel-related substances in emulsion formulations, with the primary degradation products.
Downloads
Metrics
References
Klick S, Muijselaar PG, Waterval J, et al. (2005) Stress testing of drug substances and drug products. Pharm Technol. Vol 29(2):48-66.
Cione AP, Tonhi E and Silva P (2011) Stability Indicating Methods. Quality Control of Herbal Medicines and Related Areas Edited by Prof. Yukihiro Shoyama, , ISBN 978-953-307-682-9; pp. 25-36
Singh S, Junwal M, Modhe G, et al. (2013) Forced degradation studies to assess the stability of drugs and products. TrAC Trends in Analytical Chemistry. Vol 49:71-88.
Singh R, Rehman ZU (2012) Current trends in forced degradation study for pharmaceutical product development. Journal of Pharmaceutical Education and Research. Vol 3(1):54.
Alsante KM, Martin L and Baertschi SW (2003) A stress testing benchmarking study. Pharmaceutical technology. Vol 27(2):60-73.
Cione AP, Tonhi E and Silva P (2011) Stability Indicating Methods. Quality Control of Herbal Medicines and Related Areas Edited by Prof. Yukihiro Shoyama, ISBN 978-953-307-682-9; pp. 25-36
Tamizi E and Jouyban A (2016) Forced degradation studies of biopharmaceuticals: Selection of stress conditions. European Journal of Pharmaceutics and Bio pharmaceutics. Vol 98:26-46.
Tonnesen HH (2001) Formulation and stability testing of photolabile drugs. International Journal of pharmaceutics. Vol. 225(1-2):1-4.
Shinde NG, Bangar BN, Deshmukh SM, et al. (2013) Pharmaceutical forced degradation studies with regulatory consideration. Asian Journal of Research in Pharmaceutical Science. Vol 3(4):178-88.
Alsante KM, Ando A, Brown R, et al. (2007) the role of degradant profiling in active pharmaceutical ingredients and drug products. Advanced drug delivery reviews. Vol. 59(1):29-37.
Maheswaran R (212) scientific considerations of forced degradation studies in and a submissions. Journal of Gxp Compliance. Vol. 16(2):16.
Rao RN and Nagaraju V (2003) an overview of the recent trends in development of HPLC methods for determination of impurities in drugs. Journal of Pharmaceutical and Biomedical Analysis. Vol. 33(3):335-77.
Saimalakondaiah D, Kumar VR, Reddy TR, et al. (2014) Stability indicating HPLC method development and validation. Int. J. Pharma Res. Rev. Vol. 3:46-57.
Hawe A, Wiggenhorn M, van de Weert M, et al. (2012) Forced degradation of therapeutic proteins. Journal of pharmaceutical sciences. Vol. 101(3):895-913.
Gupta V, Jain AD, Gill NS, et al. (2012) Development and validation of HPLC method-a review. International research journal of pharmaceutical and applied sciences. Vol. 2(4):17-25.
Sangshetti JN, Deshpande M, Zaheer Z, et al. (2017) Quality by design approach: Regulatory need. Arabian Journal of chemistry. Vol. 10:S3412- 25.
Hubert C, Lebrun P, Houari S, et al. (2014) Improvement of a stability-indicating method by Quality-by-Design versus Quality-by-Testing: A case of a learning process. Journal of pharmaceutical and biomedical analysis. Vol 88:401-9.
Raman NV, Mallu UR and Bapatu HR (2015) Analytical quality by design approach to test method development and validation in drug substance manufacturing. Journal of Chemistry. Vol. 1 2015.
Orlandini S, Pinzauti S and Furlanetto S (2013) Application of quality by design to the development of analytical separation methods. Analytical and bio analytical chemistry. Vol. 405(2-3): 443-50.
Bhutani H, Kurmi M, Singh S, et al. (2004) Quality by design (QbD) in analytical sciences: an overview. Quality Assurance. Vol 3: 1-10.
Huang J, Kaul G, Cai C, et al. (2009) Quality by design case study: an integrated multivariate approach to drug product and process development. International journal of pharmaceutics. Vol 382(1-2): 23-32.
Sahu PK, Ramisetti NR, Cecchi T, et al. (2018) an overview of experimental designs in HPLC method development and validation. Journal of pharmaceutical and biomedical analysis. Vol. 147:590-611.
El‐Sayed MA and Abdul‐Azim Mohammad M. (2009) Stability‐indicating chemometric methods for the determination of pyritinol dihydrochloride. Drug testing and analysis. Vol. 1(5):228-33.
Ahuja S, and Rasmussen H (2007) HPLC Method Development for Pharmaceuticals. Academic Press, pp. 34-40.
Kats R. (2005) Forced Degradation Studies: Regulatory Considerations and Implementation. Biopharma International, Vol 01, 2005.
Reynolds D et al. (2002) Available Guidance and Best Practices for Conducting Forced Degradation Studies. Pharmaceutical Technology, Vol 2(3) 1-10.
ICH (2009) Pharmaceutical Development Q8 (R2), International Conference on Harmonisation, IFPMA, Geneva (Switzerland).
USFDA, (2004) Guidance for Industry: PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, Food and Drug Administration, Rockville, MD.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
